Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 15;123(10):1714-1720.
doi: 10.1002/cncr.30528. Epub 2017 Mar 23.

Risk-reducing salpingectomy: Let us be opportunistic

Kara C Long Roche  1 , Nadeem R Abu-Rustum  1 , Mlica Nourmoussavi  1 , Oliver Zivanovic  1
Affiliations
Review

Risk-reducing salpingectomy: Let us be opportunistic

Kara C Long Roche et al. Cancer. .

Erratum in

Abstract

Because there is no screening test for ovarian cancer, effective prevention strategies may be the best way to reduce the mortality of this most lethal gynecologic malignancy. Increasing evidence supports the hypothesis that the fallopian tube is the site of origin for the vast majority of high-grade serous carcinomas. Our growing understanding of the pathogenesis of this disease offers a rare opportunity to explore new preventive measures, such as bilateral salpingectomy, which may provide great benefit without compromising ovarian function. If the tubal paradigm is accurate, then the impact of bilateral salpingectomy could extend to BRCA1 and BRCA2 mutation carriers, high-risk noncarriers, and average-risk women. The authors present a review of the literature on the role of risk-reducing salpingectomy in all women and in high-risk groups, with a focus on morbidity, ovarian function, potential clinical applicability, and epidemiological considerations. Cancer 2017;123:1714-1720. © 2017 American Cancer Society.

Keywords: fallopian tubes; high-grade serous carcinoma; ovarian cancer; ovarian function; salpingectomy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: There are no conflict of interest disclosures from any of the authors.

Comment in

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
    1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–2529. - PubMed
    1. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295–2303. - PubMed
    1. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007;107:159–162. - PubMed
    1. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer. 2000;83:1301–1308. No authors listed. - PMC - PubMed

MeSH terms